Key influences in MDT treatment decision making • Medical & Family History, Performance Status & Co-morbidities (ot • Associated Syndromes (presence or absence of neuroendocrine ca • Primary site • Stage (I – IV) • Histology (Cell type, Grade: Ki67% / Mitotic rate) • Laboratory (Blood / Urine) & Radiology (Scan) Results • Functional imaging results (Gallium / Octreotide, MiBG or FDG-PE • Guidelines (Local, National, European & International) & Research • Availability and accessibility of ‘best’ treatment option – including C • Patient personal considerations (beliefs, preferences, geographica • Pre-habilitation and Rehabilitation (pre and post-treatment) require Questions the team may discuss in the meeting, when reviewing results available for you Medical & Family History, Performance Status* & Co-morbidities** • What led to you being referred: what symptoms did / do you have? • How was the possibility of neuroendocrine cancer raised / confirmed? • What other health conditions do you or have you had? • Have you ever had surgery before? If so, what was surgery for? • Is there a family history of neuroendocrine cancer or other cancers / conditions that may or may not be related? • What is your current health like - how well are you*? • Do you have any other health conditions** - how are they being treated?
Made with FlippingBook - Share PDF online